Because patients with IBD are already anxious about getting sick with COVID-19, it should be made clear to them that although their cellular immunity may be reduced with anti-TNF therapy, they are not at increased risk of experiencing worse COVID-19 related outcomes compared to the general population [30]. This evidence concerns the gene TNF and COVID-19.